Astrana Health (3AM) Stock Forecast & Price Target

0 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

3AM Analyst Ratings

Strong Buy

7 Buy

1 Hold

0 Sell

Based on 8 analysts giving stock ratings to

Astrana

Health

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

3AM Stock 12 Month Forecast

Average Price Target

€45.35

▲(43.51% Upside)

Based on 8 Wall Street analysts offering 12 month price targets for Astrana Health in the last 3 months. The average price target is €45.35 with a high forecast of €55.79 and a low forecast of €35.19. The average price target represents a 43.51% change from the last price of €31.60.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"16":"€16","26":"€26","36":"€36","46":"€46","56":"€56"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":55.7934169,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€55.79</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":45.35003373666667,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€45.35</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":35.19277066,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€35.19</span>\n  </div></div>","useHTML":true}}],"tickPositions":[16,26,36,46,56],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,31.4,33.276416684615384,35.15283336923077,37.029250053846155,38.905666738461534,40.78208342307692,42.658500107692305,44.53491679230769,46.411333476923076,48.287750161538455,50.16416684615385,52.040583530769226,53.91700021538461,{"y":55.7934169,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,31.4,32.473079518205125,33.54615903641025,34.619238554615386,35.69231807282051,36.76539759102564,37.838477109230766,38.9115566274359,39.984636145641026,41.05771566384615,42.13079518205128,43.20387470025641,44.27695421846154,{"y":45.35003373666667,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,31.4,31.69175158923077,31.983503178461536,32.27525476769231,32.56700635692307,32.858757946153844,33.150509535384614,33.442261124615385,33.734012713846155,34.025764303076926,34.31751589230769,34.60926748153846,34.90101907076923,{"y":35.19277066,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":20,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.9,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.4,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.8,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.3,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.2,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.8,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.8,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.6,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.6,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.8,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.4,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€55.79

Average Price Target€45.35

Lowest Price Target€35.19

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Andrew Mok CFA

Barclays

€45.49

Buy

43.97%

Upside

Reiterated

08/28/26

Barclays Sticks to Their Buy Rating for Astrana Health (ASTH)

Jailendra Singh

Truist Financial

€40.34→€47.21

Buy

49.40%

Upside

Reiterated

08/11/26

Analysts Offer Insights on Healthcare Companies: Beam Therapeutics (NASDAQ: BEAM), OmniAb (NASDAQ: OABI) and Astrana Health (NASDAQ: ASTH)

David Larsen

BTIG

€55.79

Buy

76.56%

Upside

Reiterated

08/09/26

Astrana Health: Robust Revenue Growth, Margin Upside Drive Buy Rating with Unchanged $65 Price Target

Matthew Shea

Needham

€35.19

Buy

11.37%

Upside

Reiterated

08/07/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Astrana Health (NASDAQ: ASTH), Hyperfine (NASDAQ: HYPR) and Organogenesis Holdings (NASDAQ: ORGO)

Matthew Gillmor CFA

KeyBanc

―

Hold

―

Reiterated

08/07/26

Analysts Conflicted on These Healthcare Names: Astrana Health (NASDAQ: ASTH), Resmed (NYSE: RMD) and Definium Therapeutics (NASDAQ: DFTX)

Ryan Daniels

William Blair

―

Buy

―

Reiterated

08/06/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Astrana Health (NASDAQ: ASTH) and ALX Oncology Holdings (NASDAQ: ALXO)

Ryan Langston

TD Cowen

€42.92

Buy

35.82%

Upside

Assigned

07/14/26

Analysts Are Bullish on These Healthcare Stocks: Astrana Health (ASTH), ArriVent BioPharma, Inc. (AVBP)

Jack Slevin

Jefferies

€45.49

Buy

43.97%

Upside

Reiterated

06/30/26

Astrana Health (ASTH) Gets a Buy from Jefferies

Michael Craig Jones

Bank of America Securities

―

Buy

―

Reiterated

05/13/26

Analysts Offer Insights on Healthcare Companies: Astrana Health (NASDAQ: ASTH), Bristol-Myers Squibb (NYSE: BMY) and Progyny (NASDAQ: PGNY)

Michael Ha

Robert W. Baird

€34.33→€38.63

Buy

22.23%

Upside

Reiterated

05/08/26

Astrana Health price target raised to $45 from $40 at BairdAstrana Health price target raised to $45 from $40 at Baird

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Andrew Mok CFA

Barclays

€45.49

Buy

43.97%

Upside

Reiterated

08/28/26

Barclays Sticks to Their Buy Rating for Astrana Health (ASTH)

Jailendra Singh

Truist Financial

€40.34→€47.21

Buy

49.40%

Upside

Reiterated

08/11/26

Analysts Offer Insights on Healthcare Companies: Beam Therapeutics (NASDAQ: BEAM), OmniAb (NASDAQ: OABI) and Astrana Health (NASDAQ: ASTH)

David Larsen

BTIG

€55.79

Buy

76.56%

Upside

Reiterated

08/09/26

Astrana Health: Robust Revenue Growth, Margin Upside Drive Buy Rating with Unchanged $65 Price Target

Matthew Shea

Needham

€35.19

Buy

11.37%

Upside

Reiterated

08/07/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Astrana Health (NASDAQ: ASTH), Hyperfine (NASDAQ: HYPR) and Organogenesis Holdings (NASDAQ: ORGO)

Matthew Gillmor CFA

KeyBanc

―

Hold

―

Reiterated

08/07/26

Analysts Conflicted on These Healthcare Names: Astrana Health (NASDAQ: ASTH), Resmed (NYSE: RMD) and Definium Therapeutics (NASDAQ: DFTX)

Ryan Daniels

William Blair

―

Buy

―

Reiterated

08/06/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Astrana Health (NASDAQ: ASTH) and ALX Oncology Holdings (NASDAQ: ALXO)

Ryan Langston

TD Cowen

€42.92

Buy

35.82%

Upside

Assigned

07/14/26

Analysts Are Bullish on These Healthcare Stocks: Astrana Health (ASTH), ArriVent BioPharma, Inc. (AVBP)

Jack Slevin

Jefferies

€45.49

Buy

43.97%

Upside

Reiterated

06/30/26

Astrana Health (ASTH) Gets a Buy from Jefferies

Michael Craig Jones

Bank of America Securities

―

Buy

―

Reiterated

05/13/26

Analysts Offer Insights on Healthcare Companies: Astrana Health (NASDAQ: ASTH), Bristol-Myers Squibb (NYSE: BMY) and Progyny (NASDAQ: PGNY)

Michael Ha

Robert W. Baird

€34.33→€38.63

Buy

22.23%

Upside

Reiterated

05/08/26

Astrana Health price target raised to $45 from $40 at BairdAstrana Health price target raised to $45 from $40 at Baird

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

ODTXOdyssey Therapeutics, Inc.

BTSGBrightSpring Health Services, Inc.

GPCRStructure Therapeutics, Inc. Sponsored ADR

AMLXAmylyx Pharmaceuticals Inc

IMMXImmix Biopharma

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Astrana Health

3 Months

David LarsenBTIG

Success Rate

10/15 ratings generated profit

Average Return

+6.08%

Copying David Larsen's trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +6.08% per trade.

1 Year

Ryan DanielsWilliam Blair

Success Rate

8/10 ratings generated profit

Average Return

+36.21%

Copying Ryan Daniels's trades and holding each position for 1 Year would result in 80.00% of your transactions generating a profit, with an average return of +36.21% per trade.

2 Years

Ryan DanielsWilliam Blair

Success Rate

10/10 ratings generated profit

Average Return

+47.78%

Copying Ryan Daniels's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +47.78% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

3AM Analyst Recommendation Trends

Rating

Apr 26

May 26

Jun 26

Jul 26

Aug 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 3AM has received 12 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. 3AM average Analyst price target in the past 3 months is 45.35.

Each month's total comprises the sum of three months' worth of ratings.

3AM Financial Forecast

3AM Earnings Forecast

Next quarter’s earnings estimate for 3AM is €0.38 with a range of €0.30 to €0.46. The previous quarter’s EPS was €0.34. 3AM beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 3AM has Performed in-line its overall industry.

3AM Sales Forecast

Next quarter’s sales forecast for 3AM is €875.87M with a range of €864.30M to €883.68M. The previous quarter’s sales results were €834.77M. 3AM beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 3AM has Performed in-line its overall industry.

3AM Stock Forecast FAQ

What is DE:3AM’s average 12-month price target, according to analysts?

Based on analyst ratings, Astrana Health’s 12-month average price target is 45.35.

What is DE:3AM’s upside potential, based on the analysts’ average price target?

Astrana Health has 43.51% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Astrana Health a Buy, Sell or Hold?

Astrana Health has a consensus rating of Strong Buy, which is based on 7 buy ratings, 1 hold ratings and 0 sell ratings.

What is Astrana Health’s share price target?

The average share price target for Astrana Health is 45.35. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €55.79 ,and the lowest forecast is €35.19. The average share price target represents 43.51% Increase from the current price of €31.6.

What do analysts say about Astrana Health?

Astrana Health’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.

How can I buy shares of Astrana Health?

To buy shares of DE:3AM, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Astrana Health (3AM) Stock Forecast & Price Target

3AM Analyst Ratings

3AM Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Astrana Health

3AM Analyst Recommendation Trends

3AM Financial Forecast

3AM Earnings Forecast

3AM Sales Forecast

3AM Stock Forecast FAQ

Detailed List of Analyst Forecasts